EUCTR2008-004429-41-ES进行中（未招募）1 期
Estudio de fase II, aleatorizado, doble ciego, para evaluar la eficacia y la seguridad de sorafenib comparado con placebo en pacientes con cáncer epitelial de ovario o con cáncer peritoneal primario que han alcanzado una respuesta clínica completa después de quimioterapia estándar con platino/taxano. (A Double-Blind, Randomized Phase II Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo in Ovarian Epithelial Cancer or Primary Peritoneal Cancer Patients who have achieved a Complete Clinical Response after Standard Platinum/Taxane Containing Chemotherapy)
Bayer Healthcare AG, D-51368 Leverkusen, Germany0 个研究点目标入组 0 人开始时间: 2008年11月25日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •- Patients must be able and willing to sign a written informed consent. A signed informed consent must be appropriately obtained prior to any study specific procedures.
- •- Age ?18 years.
- •- Histologically confirmed FIGO stage III or IV ovarian epithelial cancer or primary peritoneal cancer at presentation. Patients must have achieved a clinical complete response (disappearance of all clinical and radiological evidence of tumor) after only one regimen (4-6 cycles) of platinum and taxane-based standard chemotherapy received after tumor debulkment. No previous chemotherapy can be administered except for the one regimen for ovarian or primary peritoneal cancer.
- •- Normal serum CA125 level within 7 days of first dose of sorafenib.
- •- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- •- All scans used to document complete response must be done within 30 days prior to randomization.
- •- Patients must be able to swallow and retain oral medication.
- •- Life expectancy of at least 12 weeks.
- •- Adequate bone marrow, liver and renal function as assessed by the following laboratory requirements to be conducted within 7 days prior to screening:
- •- Hemoglobin ?8.5 g/dl
- •- Absolute neutrophil count (ANC) ?1,500/mm3
- •- Platelet count ? 75,000/µl
- •- Total bilirubin ? 1.5 times the upper limit of normal
- •- Alanine transaminase (ALT) and Aspartate aminotransferase (AST) ? 2.5 x upper limit of normal
- •- Alkaline phosphatase ? 4 x upper limit of normal (ULN)
- •- Prothrombin time (PT)/international normalized ratio (INR) and partial thromboplastin time (PTT) < 1.5 x ULN
- •- Serum creatinine ? 1.5 x ULN.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- Patients with any residual cancer tissue after the completion of chemotherapy detectable by standard CT or magnetic resonance imaging (MRI).
- •- Prior local radiotherapy, neoadjuvant chemotherapy or intraperitoneal chemotherapy for any current or prior diagnosis of ovarian or primary peritoneal cancer.
- •- Histologic subtypes of ovarian cancer other than epithelial (i.e. sarcoma, lymphoma, germ cell).
- •- Major surgery, open biopsy, or significant traumatic injury within 30 days prior to randomization.
- •- Non-healing wound, ulcer, or bone fracture.
- •- Evidence or history of bleeding diathesis or coagulopathy.
- •- Clinically significant cardiac disease including congestive heart failure > class II New York Heart Association (NYHA), unstable angina (angina symptoms at rest), new-onset angina (begun within the last 3 months) or myocardial infarction within the past 6 months prior to randomization.
- •- Cardiac ventricular arrhythmias requiring anti-arrhythmic therapy or uncontrolled hypertension (systolic blood pressure > 150 mmHg or diastolic pressure > 90 mmHg) despite optimal medical management.
- •- Thrombotic or embolic venous or arterial events, such as a cerebrovascular accident, including transient ischemic attacks and pulmonary embolism within the past 6 months.
- •- Hemorrhage/bleeding event ? NCI-Common Terminology Criteria for Adverse Events (CTCAE) Grade 3 within 30 days of randomization.
- •- Infection > NCI-CTCAE Grade 2.
- •- Known human immunodeficiency virus infection or infection with hepatitis B or C.
- •- Previous or concurrent cancer that is distinct in primary site or histology from ovarian or primary peritoneal cancer within 5 years prior to randomization EXCEPT cervical cancer in situ, treated basal cell carcinoma and superficial bladder tumors [Ta (Non invasive tumor), Tis (Carcinoma in situ) and T1 (Tumor invades lamina propria)].
- •- Known or suspected allergy to sorafenib or hypersensitivity to sorafenib or any agent given in the course of this trial.
- •- Patients with seizure disorder requiring medication (such as steroids or anti-epileptics).
- •- Patients undergoing renal dialysis.
- •- Substance abuse, medical, psychological or social conditions that may interfere with the patient?s participation in the study or evaluation of the study results.
- •- Unresolved toxicity (i.e. neurotoxicity) attributed to the required chemotherapy higher than NCI-CTCAE (version 3) Grade 2 (excluding cases of alopecia).
- •- Patients unable to swallow oral medications.
- •- Any malabsorption condition.
- •- Any condition that is unstable or could jeopardize the safety of the patient and their compliance in the study.
- •- Known brain metastasis. Patients with unexplained neurological symptoms will undergo a CT scan/MRI of the brain to exclude brain metastasis.
研究者
相似试验
进行中（未招募）
不适用
Estudio de fase II, aleatorizado, doble ciego de exemestano +/- MM-121 en mujeres posmenopáusicas con cáncer de mama Her2 negativo localmente avanzado o metastásico, con receptores de estrógeno positivo (ER+) y/o receptores de progesterona positivos (RP+)_______A Randomized, Double-Blind Phase 2 trial of Exemestane +/- MM-121 in Postmenopausal Women with Locally Advanced or Metastatic Estrogen Receptor Positive (ER+) and/or Progesterone Receptor Positive (PR+), Her2 negative Breast Cancercáncer de mama_____Breast cancerMedDRA version: 12.1Level: LLTClassification code 10006187Term: Breast cancerEUCTR2010-020395-28-ESMERRIMACK PHARMACEUTICALS130
进行中（未招募）
不适用
Estudio de fase II, aleatorizado, doble ciego, controlado con placebo, del inhibidor de MEK GSK1120212 y Gemcitabina frente a placebo y Gemcitabina en sujetos con cáncer de páncreas metastásico. A Randomized, Double-Blind Placebo-Controlled Phase II Study of the MEK inhibitor GSK1120212 plus Gemcitabine vs. Placebo plus Gemcitabine in Subjects with Metastatic Pancreatic CancerCáncer de páncreas metastásicoMedDRA version: 13Level: LLTClassification code 10033605Term: Cáncer pancreático metastásicoEUCTR2010-019578-34-ESGlaxoSmithKline, S.A.150
进行中（未招募）
1 期
Estudio en fase II aleatorizado, doble ciego y multicéntrico, para evaluar la eficacia de AZD2281 en el tratamiento de pacientes con cáncer de ovario seroso sensible al platino tras el tratamiento con dos o más regímenes que contienen platino.Phase II randomised, double blind, multicentre study to assess the efficacy of AZD2281 in the treatment of patients with platinum sensitive serous ovarian cancer following treatment with two or more platinum containing regimensCáncer seroso de ovario sensible al platinoPlatinum sensitive serous ovarian cancerMedDRA version: 9.1Level: LLTClassification code 10033128Term: Ovarian cancerEUCTR2008-003439-18-ESAstraZeneca AB250
进行中（未招募）
1 期
Estudio de fase 2, aleatorizado, a doble ciego y controlado con placebo para evaluar la seguridad y eficacia de FOLFIRI en combinación con AMG 479 o AMG 655 en comparación con FOLFIRI en el tratamiento de segunda línea del carcinoma colorrectal metastásico con KRAS mutado.A Phase 2, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safetyand Efficacy of FOLFIRI in Combination With AMG 479 or AMG 655 Versus FOLFIRI for the Second-line Treatment of KRAS-mutant Metastatic Colorectal CarcinomaEUCTR2008-005301-19-ESAmgen Inc150
进行中（未招募）
1 期
Estudio de fase II, doble ciego, aleatorizado y controlado con placebo para determinar el efecto antiviral, la seguridad y la farmacocinética de la administración una vez al día durante 12 ó 24 semanas de BI 201335 NA, junto a la administración de interferón pegilado? 2a y ribavirina en pacientes con hepatitis C de genotipo 1 no tratados previamente.Antiviral effect, safety and pharmacokinetics of once daily BI 201335 NA in hepatitis C virus genotype 1 infected treatment-naïve patients for 12 or 24 weeks as combination therapy with pegylated interferon-? 2a and ribavirin (double-blinded, randomised, placebo-controlled, Phase II).infección crónica por el virus de la hepatitis C del genotipo 1chronic hepatitis C infection of genotype 1EUCTR2008-003538-11-ESBoehringer Ingelheim España, S.A.420